Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Iain Ross, Steven Paul, Mark Levin

Premium

Biotech firm Amarantus Bioscience has appointed Iain Ross to its board of directors.

Ross is currently chairman of Ark Therapeutics and Biomer Technology. He is also a non-executive director of expressed RNAi firm Benitec Biopharma, and previously served as chairman of Silence Therapeutics.


Voyager Therapeutics has named Steven Paul, its interim president of research and development, as its new CEO.

Paul replaces Third Rock Venture partner Mark Levin, who served as the startup's interim CEO following the venture capital company's investment in Voyager earlier this year. Levin has now become Voyager's chairman.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.